GLUE

Aug 6, 2026, 00:00 UTC

Monte Rosa Therapeutics reported its Q2 2026 financial results, with collaboration revenue of $9.0 million, a net loss of $43.4 million, and cash and investments of $626.0 million as of June 30, 2026.